-
Rapid Detection & Differentiation of SARS-CoV-2, FLU A or B
-
Accurate Results Within 15 Minutes
-
Uses BD Veritor Analyzer to Analyze and Display Results
-
Advanced Particle Technology for Enhanced Sensitivity
-
Adaptive Read Technology for Increased Specificity
-
Reduces Instances of False Positives
-
FDA EUA, Pending FDA Clearance
-
Shelf Life: 485 Days .

The BD Veritor SARS-CoV-2 & Influenza A+B Rapid Detection Kit (30/kit) tests for three respiratory viruses (SARS-CoV-2 & Flu A, and Flu B) with just one nasal specimen. This rapid test requires the BD Veritor Plus Analyzer (sold separately) and Upgrade Key for analysis.

FAST, DIGITAL MULTI-VIRUS DETECTION
TRIPLE-TARGET TESTING: Detects and differentiates SARS-CoV-2, Influenza A, and Influenza B in a single test.
SIMPLE WORKFLOW: Collect a sample with a nasal swab, mix it with the extraction reagent, apply it to the test device, and run it on the analyzer after 15 minutes.
AUTOMATED ACCURACY: The BD Veritor™ Analyzer provides clear digital results, eliminating subjective line interpretation and reducing human error.
IMPROVED CLINICAL DECISIONS: On-site identification supports faster treatment decisions, patient isolation, and public health response.
FDA Disclaimer: This combination test is not FDA cleared or approved, but only authorized under an Emergency Use Authorization for use by authorized laboratories. It is authorized for the rapid detection of proteins from SARS-CoV-2, Influenza A & Influenza B and not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
WARNING: This product can expose you to chemicals known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.